Feb. 19, 2025 — A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have ...

Feb. 6, 2025 — Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even ...

Clene will join APST Research to explore how CNM-Au8 affects NfL levels in ALS patients treated in expanded access programs.

引言在与癌症的博弈中，脑转移始终是最凶险的战场。每年全球23万非小细胞肺癌患者中，40%会遭遇癌细胞向大脑的致命迁徙——这种隐秘的转移犹如"定时炸弹"，确诊时往往已形成多发病灶，使患者中位生存期骤降至不足6个月。尽管靶向治疗和免疫疗法不断革新，脑转移 ...

The LAG-3 next-generation therapies market is expected to grow in the upcoming years owing to the potential entry of major LAG-3 candidates and their readily uptake, increase in incident cases of ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever ...

ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...

为探究类风湿关节炎（RA）与非小细胞肺癌（NSCLC）的关联，北京大学肿瘤医院云南分院的研究人员开展相关研究，发现 RA 治疗药物 TNF 抑制剂或增 NSCLC 风险，为疾病研究及治疗提供新视角。

Canaan Partners, Menlo Park, California.

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and tr ...